WELCOME TO CTX PLATFORMS
TRANSLATING AEONS OF EVOLUTION TO CURRENT CLINICAL PRACTICE
CANCER TARGETED BIMODAL CONTRAST AGENT
Contrast agent guided neurosurgery for improved demarcation is available both at preoperative planning (MRI) as well as intraoperative near infrared guidance (NIRF open field camera)
TARGETED IMMUNOTHERAPY FOR CANCER
Using synthetically engineered knotting peptides drug delivery is an easier approach to penetrate the BBB than moAbs
NEAR INFRARED GUIDED ENDOSCOPIES
Targeted fluorescence technology for endoscopic and open field GI procedures. These include higher sensitivity for early detection of adenomatous polyps as well as improved complete polypectomies.
CANCER TARGETED RADIOLIGAND
Isotopes conjugated to the bio-carrier enable the demonstration of staging via gamma camera or PET-CT as well as targeted radiotherapy specifically to the affected tissue.
CTX Platforms is a biotech company located in Israel, which develops advanced targeted technology applications for various cancers. It is inspired by nature and harnessed to clinical oncology.
The company is developing specific proteins to serve as biocarriers. These proteins are derived from various scorpion venoms, expressing unique characteristics, namely, selective affinity to cancer tissues, high stability, and effective penetrability to the blood-brain barrier (BBB). The R&D division is built to discover new proteins from various scorpions and create a pipeline for future bio-carriers for applications in cancer theranostics.
CTX Platforms is currently supported by the Israeli Innovation Authority and has advanced in the POC stage in vitro. The company is before round-A investment, currently engaged in due diligence process with an EU fund.
For more information about our work, email us and we will be happy to share our enthusiasm with you.